Phathom Pharmaceuticals Inc Net Assets
Phathom Pharmaceuticals Inc net assets. Based on the latest financial reports, Phathom Pharmaceuticals Inc (PHAT) has net assets worth $-422.53 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($240.29 Million) and total liabilities ($662.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Phathom Pharmaceuticals Inc to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-422.53 Million |
| % of Total Assets | -175.84% |
| Annual Growth Rate | N/A |
| 5-Year Change | -230.53% |
| 10-Year Change | N/A |
| Growth Volatility | 80.16 |
Net Assets of Phathom Pharmaceuticals Inc (2018–2024)
Net assets of Phathom Pharmaceuticals Inc from 2018 to 2024. This chart illustrates how Phathom Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. See PHAT net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Phathom Pharmaceuticals Inc (2018–2024)
The table below shows the annual net assets of Phathom Pharmaceuticals Inc from 2018 to 2024. For live market cap and overall valuation, see PHAT company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-253.58 Million | -248.52% |
| 2023-12-31 | $-72.76 Million | +2.75% |
| 2022-12-31 | $-74.81 Million | -203.68% |
| 2021-12-31 | $72.16 Million | -62.86% |
| 2020-12-31 | $194.27 Million | -14.78% |
| 2019-12-31 | $227.96 Million | +17825.89% |
| 2018-12-31 | $-1.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Phathom Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 126172300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Phathom Pharmaceuticals Inc Net Assets Breakdown (December 2024)
Phathom Pharmaceuticals Inc net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | % |
| Other Components | $1.01 Billion | % |
| Total Equity | $-253.58 Million | 100.00% |
Phathom Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Phathom Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
$447.88 Million |
|
Churchill Capital Corp XI
NASDAQ:CCXI
|
$447.91 Million |
|
Chengdu Lihang Technology Co.Ltd.
SHG:603261
|
$447.99 Million |
|
Quality Houses Public Company Limited
BK:QH
|
$448.19 Million |
|
BlackRock Energy and Resources Closed Fund
NYSE:BGR
|
$447.77 Million |
|
Hap Seng Plantations Holdings Bhd
KLSE:5138
|
$447.73 Million |
|
Oriental Union Chemical Corp
TW:1710
|
$447.62 Million |
|
Lafang China
SHG:603630
|
$447.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Phathom Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -72,759,000 to -253,580,000, a change of -180,821,000.
- Net loss of 334,326,000 reduced equity.
- New share issuances of 121,775,000 increased equity.
- Other factors increased equity by 31,730,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-334.33 Million | -131.84% |
| Share Issuances | $121.78 Million | +48.02% |
| Other Changes | $31.73 Million | +12.51% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Phathom Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.15 | $5.74 | x |
| 2019-12-31 | $9.22 | $5.74 | x |
| 2020-12-31 | $5.85 | $5.74 | x |
| 2021-12-31 | $1.95 | $5.74 | x |
| 2022-12-31 | $-1.91 | $5.74 | x |
| 2023-12-31 | $-1.42 | $5.74 | x |
| 2024-12-31 | $-4.01 | $5.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Phathom Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -605.09%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-51.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.16 Million |
| 2019 | -92.01% | 0.00% | 0.00x | 1.13x | $-232.54 Million |
| 2020 | -66.44% | 0.00% | 0.00x | 1.52x | $-148.50 Million |
| 2021 | -199.41% | 0.00% | 0.00x | 2.63x | $-151.10 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-190.24 Million |
| 2023 | 0.00% | -29558.94% | 0.00x | 0.00x | $-194.32 Million |
| 2024 | 0.00% | -605.09% | 0.15x | 0.00x | $-308.97 Million |
Industry Comparison
This section compares Phathom Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Phathom Pharmaceuticals Inc (PHAT) | $-422.53 Million | 0.00% | N/A | $447.80 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical t… Read more